Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45445 | 0.94 | HSD17B10 (0.42) | HSD17B10HTR1APOLBDRD4CYP2C19 | |
| SCHEMBL45171 | 0.90 | HSD17B10 (0.41) | HSD17B10HTR1APOLBDRD4MAPT | |
| SCHEMBL45313 | 0.88 | PRKD1 (0.40) | HSD17B10HTR1ACYP2C19MAPTMEN1 | |
| SCHEMBL45394 | 0.88 | PRKD1 (0.40) | HSD17B10HTR1ACYP2C19MAPTMEN1 | |
| SCHEMBL15752123 | 0.86 | BCL3 (0.38) | POLBCYP2C19CYP2C9MEN1KMT2A | |
| SCHEMBL45170 | 0.84 | HSD17B10 (0.41) | HSD17B10HTR1APOLBDRD4MAPT | |
| SCHEMBL11026483 | 0.83 | F10 (0.45) | CYP2C19MAPTMEN1KMT2A | |
| SCHEMBL41795 | 0.83 | MEN1 (0.35) | HSD17B10HTR1APOLBDRD4CYP2C19 | |
| SCHEMBL45257 | 0.82 | PRMT5 (0.44) | CYP2C19MAPTMEN1RAB9AKMT2A | |
| SCHEMBL45312 | 0.81 | F10 (0.47) | CYP2C19CYP2C9MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | claimed |
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-8592594-B2 | Tetrahydro-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2588458-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | GPR119, PRKAB1, PRKAG1 | HSD17B10 375/4885HTR1A 1097/4885POLB 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.